- New research presented at
Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suiteto predict a woman’s one to two-year risk for breast cancer - iCAD unveils new solution that assesses calcium deposits in the breast arteries as a proxy for hidden cardiovascular disease, the leading cause of death for women in the
U.S. - Dr.
Emily Conant ,Perelman School of Medicine ,University of Pennsylvania , to present how iCAD’s 4th generation Breast AI is harnessing innovations to improve patient outcomes
Blending artificial intelligence with computer-aided detection (AI CAD), the iCAD software platform, ProFound Breast Health Suite, can screen a single mammogram for two of the top causes of death for women: breast cancer and heart disease. ProFound AI improves accuracy, streamlines clinical workflow and delivers results to patients more quickly.
“The ProFound Breast Health Suite significantly increases cancer detection rates with up to 2x enhanced clinical performance compared to other AI platforms, and reduces the rate of false positive results while accurately evaluating a woman’s breast density and cancer risk,” said
Catching cardiovascular disease through mammography
Recent research shows that calcium deposits inside the blood vessels of the breast correlate to hardening of the cardiovascular arteries. In fact, women with breast arterial calcifications, or BAC, are 51% more likely to develop heart disease. iCAD's report on the existence of arterial calcification, along with easy-to-understand visual representations that demonstrate the extent of calcification, can help women work with their physicians to further evaluate their cardiovascular health and identify any potential need for intervention.
“Radiologists currently rely on visual detection of breast arterial calcifications, which is time-consuming and leads to a national underreporting of BAC results in mammography reports,” explained
Accurately predicting personal breast cancer risk
Axel Gräwingholt, M.D., head of mammography screening at Radiologie am Theater in
The researchers used ProFound Risk to screen the mammograms of 53,453 women who had received normal results two years earlier from their radiologists. The program flagged 42.8% of the women, or 22,878 patients, at a higher risk for breast cancer.
ProFound Risk’s prediction proved correct. The average risk for women in the study who developed breast cancer two years after their mammogram was 2.4 times higher than for those who remained cancer-free. The average risk for invasive cancers exceeded that of ductal carcinoma in situ (DCIS), a slow-growing cancer of the milk ducts.
“Our findings suggest AI enables radiologists to identify women who would benefit from more frequent screenings, or suggest supplemental screenings, without leading to overdiagnosis,” said Dr. Gräwingholt. “ProFound Risk accurately pinpoints women at high risk for breast cancer while helping us discover small, subtle and aggressive cancers that often go undetected by the naked eye. We believe this technology could greatly enhance the effectiveness of breast cancer screening strategies worldwide.”
Dr. Gräwingholt’s oral presentation will occur on
Other presentations of note:
Emily Conant , M.D., professor of Radiology and Vice Chair ofFaculty Development in theDepartment of Radiology at theUniversity of Pennsylvania ,Perelman School of Medicine , will deliver an Industry Summit presentation, “From Pixels to Practice: Harnessing Innovations in Breast AI to Improve Patient Outcomes.” showcasing promising early testing results from iCAD’s newest 4th generation AI for breast cancer detectionMonday, Nov. 27 , 3:30 –3:45 pm CST (AI Showcase Theater )Thu Ha Dao , M.D., a radiologist at Hôpitaux Universitaires Henri Mondor inFrance , will deliver a poster presentation onSunday, Nov. 26 from 12:15 –12:45 pm CST : “Evaluation of a Deep-learning based Software Tool to Automatically Detect and Quantify Breast Arterial Calcifications in Digital Mammograms.” (Session S3B-SPBR-1)Mikael Eriksson , Ph.D., a postdoctoral researcher of medical epidemiology and biostatistics at theKarolinska Institute inSweden , will deliver a poster presentation onMonday, Nov. 27 from 12:45 –1:15 pm CST : “Multi-national validation of a clinical image-based AI-risk model for individualizing breast cancer screening.” (Session M5B-SPBR-4)- iCAD staff will showcase the ProFound Breast Health Suite in an interactive exhibit for attendees demonstrating how to add and scale AI in their radiology practices. (RSNA South Hall, Booth 3940). Solutions demonstrated include:
- ProFound Detection*: both the current cleared breast cancer detection 3.0 version and future 4.0 version (4.0 not yet FDA cleared) will be available to observe for their ability to detect tumors; as well as the newest 2D version developed in collaboration with
Google Health (not yet FDA cleared or CE marked). - ProFound Density: a solution for objective, standardized assessments of breast density.
- ProFound Risk**: predicting a woman’s one- and two-year risk for developing breast cancer.
- ProFound Heart Health***: a new solution for measuring cardiovascular calcium deposits, alerting to possible vascular or heart disease (pending FDA clearance).
- ProFound Detection*: both the current cleared breast cancer detection 3.0 version and future 4.0 version (4.0 not yet FDA cleared) will be available to observe for their ability to detect tumors; as well as the newest 2D version developed in collaboration with
iCAD will also host a series of “Meet the Experts” sessions throughout the annual meeting featuring radiology, research, and technology leaders in breast imaging AI who will be available to share their experience with the ProFound Breast Health Suite. To learn more about iCAD’s presence at RSNA or to RSVP for an event, please visit https://web.icadmed.com/RSNA-2023.html
*ProFound Detection version 4.0 and ProFound Detection for 2D in partnership with
**ProFound Risk is CE Marked, Health Canada Licensed, and available for investigational use only in the
***ProFound Heart Heath is available for investigational use only, pending regulatory approval in the
About
Forward Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the
CONTACTS
Media inquiries: pr@icadmed.com
Investor Inquiries: ir@icadmed.com
Source:
2023 GlobeNewswire, Inc., source